NYSE:RDY - Dr. Reddy's Laboratories Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $70.00
  • Forecasted Upside: -2.10 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$71.50
▼ -0.59 (-0.82%)
1 month | 3 months | 12 months
Get New Dr. Reddy's Laboratories Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RDY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RDY

Average Price Target: $70.00
▼ -2.10% Downside Potential
This price target is based on 3 analysts offering 12 month price targets for Dr. Reddy's Laboratories in the last 3 months. The average price target is $70.00, with a high forecast of $70.00 and a low forecast of $70.00. The average price target represents a -2.10% upside from the last price of $71.50.

Buy

The current consensus among 3 contributing investment analysts is to buy stock in Dr. Reddy's Laboratories. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/28/2019
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/27/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/25/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/23/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/22/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/22/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/21/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/20/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/17/2021BarclaysReiterated RatingBuyLow
2/3/2021InvestecUpgradeHold ➝ BuyMedium
2/2/2021BarclaysUpgradeEqual Weight ➝ Overweight$56.00 ➝ $70.00N/A
9/18/2020Bank of AmericaUpgradeNeutral ➝ BuyLow
9/18/2020InvestecUpgradeSell ➝ HoldHigh
7/30/2020BarclaysBoost Price TargetEqual Weight$45.00 ➝ $53.00Low
4/21/2020Nomura InstinetReiterated RatingBuyMedium
1/9/2020CitigroupUpgradeSell ➝ BuyMedium
11/4/2019Bank of AmericaDowngradeBuy ➝ NeutralMedium
9/4/2019Credit Suisse GroupUpgradeUnderperform ➝ OutperformLow
7/1/2019MacquarieUpgradeNeutral ➝ OutperformLow
6/20/2019Deutsche Bank AktiengesellschaftInitiated CoverageHold ➝ HoldLow
6/11/2019BarclaysInitiated CoverageEqual Weight ➝ Equal Weight$39.00Low
5/20/2019Morgan StanleyDowngradeOverweight ➝ Equal WeightHigh
2/4/2019CL KingUpgradeNeutral ➝ BuyLow
1/17/2019CitigroupDowngradeNeutral ➝ SellLow
11/1/2017Jefferies Financial GroupLower Price TargetUnderperform$31.62 ➝ $30.51N/A
9/21/2017Morgan StanleyUpgradeEqual Weight ➝ OverweightLow
9/3/2017Jefferies Financial GroupReiterated RatingSell$31.62Medium
8/31/2017CLSAUpgradeUnderperform ➝ OutperformHigh
7/28/2017CLSADowngradeUnderperform ➝ SellLow
5/15/2017Deutsche Bank AktiengesellschaftUpgradeSell ➝ HoldHigh
7/27/2016Jefferies Financial GroupDowngradeHold ➝ Underperform$45.00 ➝ $41.90N/A
7/26/2016Credit Suisse GroupDowngradeNeutral ➝ UnderperformN/A
(Data available from 6/20/2016 forward)
Dr. Reddy's Laboratories logo
Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosage with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. It also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Proprietary Products segment focuses on the research, development, and manufacture of differentiated formulations for dermatology and neurology therapeutic areas. The company also engages in developing therapies in the fields of oncology and inflammation. As of March 31, 2020, it had four late stage projects at various stages of development. The company's therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. It has collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists; and partnership with Department of Biotechnology - Biotechnology Industry Research Assistance Council for Sputnik V vaccine clinical trials in India. The company was founded in 1984 and is headquartered in Hyderabad, India.
Read More

Today's Range

Now: $71.50
Low: $71.17
High: $71.92

50 Day Range

MA: $70.41
Low: $62.71
High: $74.20

52 Week Range

Now: $71.50
Low: $51.12
High: $74.42

Volume

215,330 shs

Average Volume

177,440 shs

Market Capitalization

$11.89 billion

P/E Ratio

45.83

Dividend Yield

0.37%

Beta

0.45

Frequently Asked Questions

What sell-side analysts currently cover shares of Dr. Reddy's Laboratories?

The following Wall Street research analysts have issued research reports on Dr. Reddy's Laboratories in the last year: Bank of America Co., Barclays PLC, Investec, and Zacks Investment Research.
View the latest analyst ratings for RDY.

What is the current price target for Dr. Reddy's Laboratories?

1 Wall Street analysts have set twelve-month price targets for Dr. Reddy's Laboratories in the last year. Their average twelve-month price target is $70.00, suggesting a possible downside of 2.1%. Barclays PLC has the highest price target set, predicting RDY will reach $70.00 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of $70.00 for Dr. Reddy's Laboratories in the next year.
View the latest price targets for RDY.

What is the current consensus analyst rating for Dr. Reddy's Laboratories?

Dr. Reddy's Laboratories currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe RDY will outperform the market and that investors should add to their positions of Dr. Reddy's Laboratories.
View the latest ratings for RDY.

What other companies compete with Dr. Reddy's Laboratories?

How do I contact Dr. Reddy's Laboratories' investor relations team?

Dr. Reddy's Laboratories' physical mailing address is 8-2-337 ROAD NO.3 BANJARA HILLS, HYDERABAD K7, 500-034. The company's listed phone number is 91-40-4900-2900 and its investor relations email address is [email protected] The official website for Dr. Reddy's Laboratories is www.drreddys.com.